(Boursier.com) — Bruno Le Maire, Minister of the Economy, Finance and Industrial and Digital Sovereignty, welcomes the decision to GSK to invest up to 350 ME on the Evreux site for the production of a new low-carbon formulation of Ventolin.
Half of GSK’s emissions are generated by their metered-dose inhaler, Ventolin – a drug that 35 million patients worldwide rely on as a rescue medication to relieve shortness of breath in asthma and COPD (chronic obstructive pulmonary disease). . A new low-carbon formulation of Ventolin is currently in clinical trials with the potential to reduce the carbon footprint of this drug by approximately 90%.
New formula
GSK has chosen its French site in Evreux (Eure) to host its investment project intended for the production of this new formulation of Ventolin. This investment of up to €350 million by the end of 2025 includes the installation of three production lines dedicated to the production of the new low-carbon formulation of Ventolin.
This project is part of the Government’s support policies for the production of medicines in the territory initiated at the request of the President of the Republic.
It is also part of the decarbonization efforts undertaken by the pharmaceutical industry, while the production and consumption linked to medicines in France represents 5% of our territory’s greenhouse gas emissions.
Roadmap
Work carried out since 2021 with the assistance of the General Directorate of Enterprises, under the aegis of the “Industry and health technologies” sector strategic committee, has made it possible to develop a roadmap aiming to achieve a reduction in energy consumption by 2030. emissions from the sector estimated between -30% to -35%.
Bruno Le Maire declared: “It is an industrial victory for France and a human victory for the employees. This investment of 350MEUR rewards the work of GSK employees in Evreux. It will create industrial activity, reduce carbon emissions from our drugs and offer low-carbon ventolin to patients in France and around the world. This is a success for the French industrial site and our drug production strategy.”
Philippe Doucet, director of the GSK Evreux site, commented: “We have already started working on this project for a new low-carbon formulation of Ventolin with the desire to make it available to patients as quickly as possible. The GSK Evreux site is already involved since 2021 in this strategic project for its research and development phase. Today, we are pleased to announce that we are going further in this project by manufacturing this new formulation in Evreux. This decision recognizes the expertise and “excellence of our site and its teams.”
©2023 Boursier.com